We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva Acquires Rights to Oncology Biosimilar Candidates
Read MoreHide Full Article
Generic drug maker Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) has entered into an exclusive biosimilar commercial partnership with Korean biopharmaceutical company Celltrion, Inc and its distribution partner Celltrion Healthcare.
Per the deal, Teva gets exclusive rights to commercialize two of Celltrion’s phase III biosimilar monoclonal antibodies (mAbs) biosimilar candidates – CT-P10 and CT-P6 – in the U.S. and Canada, pending regulatory approvals. Celltrion will, however, be responsible to finish off their clinical development and regulatory formalities.
CT-P10 is a proposed mAb biosimilar to Roche Holding AG’s (RHHBY - Free Report) drug Rituxan (rituximab) which is approved to treat non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia, rheumatoid arthritis, Wegener’s Granulomatosis and Microscopic Polyangiitis. CT-P6, on the other hand, is a proposed mAb biosimilar to Roche’s key breast cancer drug Herceptin (trastuzumab).
Both the candidates have met their primary endpoints in the respective late-stage phase III studies. While CT-P10 is under review in the EU, CT-P6 is planned to be submitted for review to the European Medicines Agency (EMA) this quarter.
Per the financial terms of the deal, Teva will pay Celltrion Healthcare $160 million upfront. Once the mAb biosimilars are commercialized, Teva and Celltrion Healthcare will share profits from the same.
The deal is in line with Teva’s plans to strengthen its biosimilar pipeline. In fact, the pharmaceutical industry is set to see an approaching wave of biosimilars, which are essentially generic versions of expensive biologic drugs.
Several pharma as well as biotech companies are involved in the development of biosimilars. The first biosimilar to gain approval in the U.S. was Sandoz’s (Novartis AG’s (NVS - Free Report) generic arm) Zarxio, a biosimilar version of Amgen Inc.’s (AMGN - Free Report) Neupogen.
Other approved biosimilars include Pfizer’s Inflectra, a biosimilar to Janssen Biotech, Inc.’s Remicade (infliximab) and Sandoz’s Erelzi, a biosimilar to Amgen’s Enbrel (etanercept). Last month, Amgen’s biosimilar version of Abbvie’s Humira – Amjevita – gained FDA aaproval.
Several other companies like Merck, Pfizer, Biogen and Allergan are targeting the highly lucrative biosimilars market.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Teva Acquires Rights to Oncology Biosimilar Candidates
Generic drug maker Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) has entered into an exclusive biosimilar commercial partnership with Korean biopharmaceutical company Celltrion, Inc and its distribution partner Celltrion Healthcare.
Per the deal, Teva gets exclusive rights to commercialize two of Celltrion’s phase III biosimilar monoclonal antibodies (mAbs) biosimilar candidates – CT-P10 and CT-P6 – in the U.S. and Canada, pending regulatory approvals. Celltrion will, however, be responsible to finish off their clinical development and regulatory formalities.
CT-P10 is a proposed mAb biosimilar to Roche Holding AG’s (RHHBY - Free Report) drug Rituxan (rituximab) which is approved to treat non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia, rheumatoid arthritis, Wegener’s Granulomatosis and Microscopic Polyangiitis. CT-P6, on the other hand, is a proposed mAb biosimilar to Roche’s key breast cancer drug Herceptin (trastuzumab).
Both the candidates have met their primary endpoints in the respective late-stage phase III studies. While CT-P10 is under review in the EU, CT-P6 is planned to be submitted for review to the European Medicines Agency (EMA) this quarter.
TEVA PHARM ADR Price
TEVA PHARM ADR Price | TEVA PHARM ADR Quote
Per the financial terms of the deal, Teva will pay Celltrion Healthcare $160 million upfront. Once the mAb biosimilars are commercialized, Teva and Celltrion Healthcare will share profits from the same.
The deal is in line with Teva’s plans to strengthen its biosimilar pipeline. In fact, the pharmaceutical industry is set to see an approaching wave of biosimilars, which are essentially generic versions of expensive biologic drugs.
Several pharma as well as biotech companies are involved in the development of biosimilars. The first biosimilar to gain approval in the U.S. was Sandoz’s (Novartis AG’s (NVS - Free Report) generic arm) Zarxio, a biosimilar version of Amgen Inc.’s (AMGN - Free Report) Neupogen.
Other approved biosimilars include Pfizer’s Inflectra, a biosimilar to Janssen Biotech, Inc.’s Remicade (infliximab) and Sandoz’s Erelzi, a biosimilar to Amgen’s Enbrel (etanercept). Last month, Amgen’s biosimilar version of Abbvie’s Humira – Amjevita – gained FDA aaproval.
Several other companies like Merck, Pfizer, Biogen and Allergan are targeting the highly lucrative biosimilars market.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>